KIRKLAND, QC, Dec. 9, 2015 /CNW Telbec/ - Manitex Capital Inc.
("Manitex") affiliate, Ortho Regenerative Technologies Inc. ("Ortho
RTi"), a Canadian orthopaedic biotechnology company, announced
today that it has appointed Dr. Ed
Margerrison as President and CEO.
"Ortho RTi is entering the next
phase of its development and the company sought out a leader with
the background to be able to bring its technology into the clinic
with human trials and lead the organization towards
commercialization" said Manitex Chairman and CEO Steve Saviuk. "Ed has the unique combination of
knowledge and experience that we were looking for".
"I am very pleased to be joining Ortho RTI at this exciting
stage in its development. Ortho
RTi's technology holds the promise to make meaningful
differences to early stage soft tissue injuries and prevent further
joint damage for patients around the globe. Our focus in the
immediate future will be to move the technology into the clinic and
prove that the unique biopolymer platform can meet these
expectations."
Dr Margerrison is an industry veteran with 25 years experience
in the orthopaedic industry. A Ph.D in molecular biology, Dr
Margerrison most recently led the biologics division of Zimmer
Inc., a multi-billion dollar leader in the orthopaedic market.
Prior to this, Dr Margerrison had spent 14 years at Smith &
Nephew Orthopaedics, leading and growing the biologics division
through development and acquisition activities.
Caution regarding forward-looking statements
This news release may contain certain forward-looking statements
regarding the Company's expectations for future events. Such
expectations are based on certain assumptions that are founded on
currently available information. If these assumptions prove
incorrect, actual results may differ materially from those
contemplated by the forward-looking statements contained in this
press release. Factors that could cause actual results to differ
include, amongst others, uncertainty as to the final result and
other risks. The Company disclaims any intention or obligation to
publicly update or revise any forward- looking statements, whether
as a result of new information, future events or otherwise, other
than as required by security laws.
About Ortho Regenerative Technologies Inc.
Ortho RTi is a Canadian
orthopaedic biotechnology company dedicated to the development of
medical devices to treat unmet needs in the orthopaedic market.
Based on a proprietary biopolymer platform, the company is
developing new regenerative treatments for soft tissue tears in the
shoulder and knee, both with few productive options for repair.
About Manitex Capital Inc.
Manitex Capital Inc. specializes in the acquisition of equity
interests in emerging life science companies and actively
participates in their management. Manitex currently has 12,561,276
common shares outstanding which are quoted for trading on the TSX
Venture Exchange.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accept responsibility for the adequacy or
accuracy of this release.
SOURCE Ortho RTI